| abstract |
Methods for treating TNF mediated diseases are provided. The methods comprise administering to patients in need there-of of therapeutically effective amount of a TNF inhibitor. In a preferred embodiment, the TNF inhibitor is selected from the group consisting of 30kDa TNF inhibitor, C105-PEG 3400 db and 40kDa TNF inhibitor, and the 40kDa TNF inhibitor is select-ed from the group consisting of full-length 40kDa TNF inhibitor, 40kDa TNF inhibitor .DELTA.51 and 40kDa TNF inhibitor .DELTA.53. A preferred method for producing the TNF inhibitors is by recombinant DNA technology. |